thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
== External links == BetaTPred3 - Insilico platform for predicting and initiating betaturns in a protein at desired location Article Link NetTurnP - Prediction of Beta-turn regions in protein sequences BetaTPred - Prediction of Beta Turns in proteins using statistical algorithms
In February 2020, 7-Eleven and GCash, the mobile wallet of Alipay and Globe Telecom, teamed up for the introduction of a new payment option for physical purchases: scan-to-pay (STP) via a barcode feature in the GCash app. This enables the customers to generate their unique barcodes through the GCash app and allow the cashier to scan their barcodes to complete the transaction. In 2020, due to the effect of COVID-19 pandemic in the Philippines, the Philippine Seven Corporation (PSC) slashed the store openings to 200 from the original 400 stores planned to be opened due to financial difficulties from the growing pandemic situation. On July 11, 2021, coinciding with the 94th founding anniversary of the convenience store chain, 7-Eleven Philippines opened its 3,000th store in Meycauayan. On October 15, 2024, as part of 7-Eleven Philippines' 40th year of operations, they opened their milestone 4,000th store in Newport, Makati.
It was the equivalent of stepping on their oxygen tube." Overall, the growth rate of per capita income in the Soviet Union between 1960 and 1989 was slightly above the world average (based on 102 countries). According to Stanley Fischer and William Easterly, growth could have been faster. By their calculation, per capita income in 1989 should have been twice higher than it was, considering the amount of investment, education and population. The authors attribute this poor performance to the low productivity of capital. Steven Rosefielde states that the standard of living declined due to Stalin's despotism. While there was a brief improvement after his death, it lapsed into stagnation. In 1987, Mikhail Gorbachev attempted to reform and revitalize the economy with his program of perestroika. His policies relaxed state control over enterprises but did not replace it by market incentives, resulting in a sharp decline in output. The economy, already suffering from reduced petroleum export revenues, started to collapse. Prices were still fixed, and the property was still largely state-owned until after the country's dissolution. For most of the period after World War II until its collapse, Soviet GDP (PPP) was the second-largest in the world, and third during the second half of the 1980s, although on a per-capita basis, it was behind that of First World countries. Compared to countries with similar per-capita GDP in 1928, the Soviet Union experienced significant growth.
Sources: en.wikipedia.org
Although the number of American teenagers who smoked cigarettes was steadily falling during the 2010s, the prevalence of electronic cigarette use was rising. As of 2019, there is no evidence linking the availability of electronic cigarettes to a decline in traditional smoking among youths. Public opinion has turned against electronic cigarettes and various state and local governments are seeking to restrict use. By the mid-2020s, tobacco product use of all types among teenagers was on the decline, a trend largely driven by falling e-cigarette demand. Bloomberg reported in 2019 that members of Generation Z were twice as likely as an average American to consume cannabis. About 1% of the number of legal marijuana consumers came this demographic cohort, and that number tripled in 2019. Generation Z is the first to be born into a time when the legalization of marijuana at the federal level is being seriously considered. As of 2019, cannabis is legal in 33 U.S. states as well as in Canada and Uruguay. Even though Generation Z may not think of cannabis as anything more than a controversial issue, there is mounting concern on its effects on human health. A survey of literature reveals that marijuana usage is linked to, among other things, impaired driving, higher risks of stroke, testicular cancer, memory loss, and certain mental illnesses, such as psychosis. Compared to those who do not use cannabis or those who start after they reach 16 years, people who start before that age suffer from reduced cognitive functioning and higher levels of impulsivity.
=== Central laboratory data === Samples collected during a clinical trial may be sent to a single central laboratory for analysis. The clinical data manager liaises with the central laboratory and agrees data formats and transfer schedules in Data Transfer Agreement. The sample collection date and time may be reconciled against the CRF to ensure that all samples collected have been analysed.
==== Belief propagation ==== In belief propagation for protein design, the algorithm exchanges messages that describe the belief that each residue has about the probability of each rotamer in neighboring residues. The algorithm updates messages on every iteration and iterates until convergence or until a fixed number of iterations. Convergence is not guaranteed in protein design. The message mi→ j(rj that a residue i sends to every rotamer (rj at neighboring residue j is defined as:
=== Cancer progression and metastasis === ITGA1 has emerged as an important mediator of pancreatic ductal adenocarcinoma (PDAC) progression. In PDAC and pancreatic intraepithelial neoplasia (PanIN), increased ITGA1 expression has been associated with aggressive disease features as well as poor prognosis of patients. Because ITGA1 is increased in premalignant lesions and encodes a cell-surface receptor, it has been proposed as a potential biomarker for early disease detection and as a therapeutic target. The ITGA1-collagen signaling axis contributes to tumor progression by regulating extracellular matrix interactions, invasion, metastatic dissemination, and resistance to chemotherapies. Increased expression of ITGA1-associated collagen ligands including type IV and type VI collagen, is also associated with aggressive tumor features, including higher tumor grade, TP53 mutation status, and erlotinib resistance. Overexpression of ITGA1 has similarly been found in other malignancies like melanoma, prostate cancer, bladder cancer, hepatocellular carcinoma, and multiple myeloma, where it is associated with invasive phenotypes, metastatic behavior and tumor progression. This association supports the identification of ITGA1 as a potential biomarker and therapeutic target across multiple cancer types.
Sources: en.wikipedia.org
A few small trials have found benefits in people with depression. A 2021 meta-analysis supports the usefulness of botox in unipolar depression, but finds significant heterogenity among the findings. The main hypothesis for its action is based on the facial feedback hypothesis. Another hypothesis involves a connection between the facial muscle and specific brain regions in animals, but additional evidence is required to support or disprove this theory.
== History == Justus von Liebig showed in 1829 that hippuric acid differed from benzoic acid and he named it, and in 1834 he determined its constitution, while in 1853 French chemist Victor Dessaignes (1800–1885) synthesized it by the action of benzoyl chloride on the zinc salt of glycine. It was also formed by heating benzoic anhydride with glycine, and by heating benzamide with monochloroacetic acid.
In October 2004 the National Agency for Urban Renewal (ANRU) signed with the municipality of Havre the first agreement to finance the rehabilitation of these areas. This finance agreement provides more than 340 million euros for the housing estates in the northern districts, where about 41,000 people reside. This development extends the budget for the Grand Projet de Ville (GPV). It allows the demolition and rebuilding of more than 1,700 homes.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.